Immunovative Inc. (“Immunovative”) (OTCBB: IMUN) today announcedthat Dr. Michael Har-Noy, Founder and Chief Executive Officer ofImmunovative Therapies, Ltd. (“ITL”), has been invited to lectureat the Division of Hematology/Oncology and the Robert H.
LurieComprehensive Cancer Center’s Grand Rounds on Friday, June 8, 2012.Grand Rounds are from 8-9 a.m. at the Robert H. Lurie MedicalResearch Center, 303 E. Superior, Gray Conference Room, Chicago,IL.
Dr. Har-Noy will be discussing the latest developments in thefield of immunotherapy of cancer and presenting data from PhaseI/II clinical trials of AlloStim™. ITl is developing a newclass of immunotherapy drugs designed to harness the power of theimmune system to treat cancer, has 11 U.S. patents granted, 17 U.S.patents pending and 26 corresponding applications pendinginternationally and has two experimental product candidates for thetreatment of cancer in clinical development: AlloStim™ andAlloVax™ Indoor Full Color LED Display
The Lurie Comprehensive Cancer Center , designated by the National Cancer Institute as a comprehensive cancer center , is the focus of cancer research, treatment, and education atNorthwestern University. The center coordinates the University’scancer and cancer-related activities and brings together more than250 basic scientists, clinical investigators, and educators fromthroughout the McGaw Medical Center. Northwestern University School of Medicine in Chicago, IL is aworld-renowned cancer research facility where faculty, fellows,postdocs and students and staff study some of the most excitingproblems in cancer treatments and technology today. Grand rounds are an integral part of medical education. Grandrounds help doctors and other healthcare professionals keep up todate in important evolving areas by presenting the newest researchand treatments in an area. Flexible LED Panels
About Immunovative Inc. About Immunovative, Inc.: On December 15, 2011, Immunovative, Inc.(“IMUN”) signed an exclusive License Agreement (the “LicenseAgreement”) with Immunovative Therapies, Ltd (“ITL”). Under theterms of the License Agreement, IMUN has been granted an exclusive,worldwide license to commercialize any products covered under ITL’scurrent issued and pending patent application portfolio, as well asthe rights to any future patent applications, includingimprovements or modifications to the existing applications and anycorresponding improvements or new versions of the existing productsincluding. About Immunovative Therapies, Ltd.: Immunovative Therapies, Ltd. is an Israeli biopharmaceuticalcompany that was founded in May 2004 with financial support fromthe Israel Office of the Chief Scientist. Outdoor LED Video Displays
Immunovative is agraduate of the Misgav Venture Accelerator, a member of theworld-renowned Israel technological incubator program. The companywas the Misgav Venture Accelerator’s candidate for the prize forthe outstanding incubator project of 2006, awarded by the Office ofthe Chief Scientist. Immunovative Therapies Ltd specializes in thedevelopment of novel immunotherapy drug products that incorporateliving immune cells as the active ingredients for treatment ofcancer and infectious disease. Please visit Immunovative’s websiteat: http://www.immunovative.co.il DISCLAIMER DISCLAIMER Forward-Looking Statements: Except for statements ofhistorical fact, this news release contains certain”forward-looking statements” as defined by the Private SecuritiesLitigation Reform Act of 1995, including, without limitationexpectations, beliefs, plans and objectives regarding thedevelopment, use and marketability of products.
Suchforward-looking statements are based on present circumstances andon IMUN’s predictions with respect to events that have notoccurred, that may not occur, or that may occur with differentconsequences and timing than those now assumed or anticipated. Suchforward-looking statements involve known and unknown risks,uncertainties and other factors, and are not guarantees of futureperformance or results and involve risks and uncertainties thatcould cause actual events or results to differ materially from theevents or results expressed or implied by such forward-lookingstatements. Such factors include general economic and businessconditions, the ability to successfully develop and marketproducts, consumer and business consumption habits, the ability tofund operations and other factors over which IMUN has little or nocontrol. Such forward-looking statements are made only as of thedate of this release, and IMUN assumes no obligation to updateforward-looking statements to reflect subsequent events orcircumstances. Readers should not place undue reliance on theseforward-looking statements.
Risks, uncertainties and other factorsare discussed in documents filed from time to time by IMUN with theSecurities and Exchange Commission. For more information, please contact: Mr. Antonio Treminio Chairman & Chief Executive Officer Immunovative, Inc. New York: +1-212-315-9705 Montreal: +1-514-840-3697 Email: Email Contact Dr. Michael Har-Noy Founder & Chief Executive Officer Immunovative Therapies, Ltd.
Israel Tel: +972-2-6506288 US Tel: +1-760-444-9040 Email: Email Contact.